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The analytical power of modern methods for DNA analysis has outstripped our 
capability to interpret and understand the data generated. To make good use of this 
genomic data in a biomedical setting (whether for research or diagnosis), it is vital 
that we understand the mechanisms through which mutations affect biochemical 
pathways and physiological systems. This lies at the centre of what genetics is all 
about, and it is the reason why genetics and genomics should go hand in hand 
whenever possible. In this Annual Review Issue of the Journal of Pathology, we have 
assembled a collection of 16 expert reviews covering a wide range of topics. Through 
these, we illustrate the power of genetic analysis to improve our understanding of 
normal physiology and disease pathology, and thereby to think in rational ways about 
clinical management. 
 
 
KEY WORDS genetics, genomics, DNA sequencing, precision medicine, complex 
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We live at a time when medical and scientific strategies often seem to struggle to 
establish themselves without the aid of fashionable new titles. The term “precision 
medicine” – only recently evolved from its apparently extinct ancestor “stratified 
medicine” – enjoys a particular vogue at the moment. The more pedantic of us may be 
inclined to regard the adjectival noun as superfluous; after all, what has medicine 
been developing towards all these many years, if not greater precision? Nonetheless, 
this phrase carries the implication that today there exist powerful new tools, with 
which the classification of disease can be refined. Better classification (i.e. better 
pathology) should of course translate into better treatment and outcome. 
 
Principal among these new tools is genetics – but should that perhaps be genomics? 
These two words are sometimes used interchangeably, which is a good enough reason 
of itself for pausing to consider the distinction. Genomics is to genetics as anatomy is 
to physiology; they are intimately related, but the former is more “what”, and the 
latter “how”. The powerful modern technologies that have captured the imaginations 
of the biomedical policy-makers are largely “genomic” – in particular, the ability to 
determine virtually complete human DNA sequences at trivial cost. For diagnostic 
purposes, it is assumed that the very large amount of genomic variability revealed in 
this way can and will be interpreted in some way and deployed for clinical benefit. 
 
It is at this point that the pluripotent champions of genomic technology tend to start 
differentiating. For some, genomic data are there to be used empirically. In this camp, 
DNA sequence variation is no more special than any other data type. Correlations 
between genotypes and phenotypes, if robust, are valid endpoints in themselves, 
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which may be used for clinical management. Though it may be forthcoming, there 
need not be any understanding of the “how”. This approach tends of necessity to be 
applied to the study of “complex” or non-Mendelian traits, since the sequence variants 
that are found to be statistically associated with particular phenotypes may not be 
susceptible to experimental analysis or mechanistic understanding. This issue is 
discussed further below. 
 
“Genetics”, though, is a bit different, and it is this that we have mostly chosen to 
focus on in the present collection of review articles. The word feels much older than 
“genomics” (the coining of which most members of the editorial team can still 
remember). However, in the sense of “the study of heredity”, as presently used, 
“genetics” is little more than a century old, the Oxford English Dictionary crediting 
its first use to William Bateson (1905). Bateson himself was a great proponent of the 
idea that important biological lessons can be learnt from the study of rare genetic 
mutants. Brought forward a century, this idea is still fresh, and indeed remains a 
driving force in research. The repeatedly fulfilled belief is that human genetic 
pathology will instruct us as to normal gene function, and in favourable cases may 
allow us to infer the likely consequences of modulating the activity of the gene 
product. 
 
Even die-hards now concede that humans are important subjects for genetic study, 
complementary to more tractable experimental organisms [1]. Whether in the 
germline or in somatic tissues, animal models of genetic disease suffer from the twin 
limitations that (a) they may fail to replicate a human pathology faithfully and (b) it 
may be infeasible to study an allelic series comprising more than a few mutations. 
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Here lie both of the great strengths and hence attractions of the human as a genetic 
model; the allelic diversity observable in naturally occurring genetic accidents in 
humans, and also the level of phenotypic detail that can be characterised, both vastly 
exceed that of any laboratory animal.  
 
In human rare disease genetics, we have now reached a stage at which most 
recognized human Mendelian phenotypes have had their genes identified. As a 
consequence, the reviews here can focus less on genes per se, and more on 
mechanisms and pathways that have been illuminated by these discoveries. In his 
often-cited Cambridge inaugural lecture, Bateson compared his newly-defined science 
of genetics to astronomy, and exalted it for showing the way to “novelty and 
adventure…hardly to be excelled” [2]. However, even he might have been surprised 
by the diversity and complexity of the processes that have revealed their secrets under 
genetic scrutiny.  
 
We begin this issue with a prime example of such complexity: McDermott and 
colleagues summarize a huge array of phenotypes that relate to impairment of the 
mechanisms regulating host responses to pathogens [3]. The physiological 
mechanisms that have been implicated in these disorders range from signalling 
through familiar cytokine axes, to aspects that were quite unknown before human 
genetic studies – such as the intimate links between viral disease, innate immunity 
and maintenance of host genome integrity [4]. One of the frequently vaunted (but less 
easily achieved) goals of “genomic medicine” is of course the advent of new, 
rationally designed therapies. Insights from these autoinflammatory disorders have 
allowed highly effective therapeutic approaches based on interleukin-1 blockade to be 
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deployed not only in rare monogenic autoinflammatory disorders but also in 
commoner diseases such as gout, in which similar disease mechanisms are at work. 
 
Another major success of genetics in unravelling a common but enigmatic disorder is 
described by Brown [5] in her review of atopic eczema. The identification of filaggrin 
as a key genetic contributor to the pathogenesis of this disorder has not only provided 
a mechanistic explanation for the development of atopy (previously regarded 
primarily as an immunological multi-system disorder), but has also focused attention 
on integrity of the epidermal barrier as a key therapeutic target. Given population 
prevalences of 10% or more for atopic disease, even marginal effects on prevention 
and treatment have enormous potential in this area. 
 
Inflammatory bowel disease (IBD) comprises a further important group of disorders 
in which immunological mechanisms play important pathogenic roles, and in which 
the genetic contributions appear complex. Uniken Venema et al. [6] directly address 
the important technical challenge referred to above; that of bridging the gap between 
statistics (genome-wide association studies) and mechanistic understanding. The 
successful recapitulation of IBD features in animal models based on several genetic 
loci identified by GWAS in IBD gives cause for optimism in this regard. 
 
A large proportion of the many present-day industrial-scale deployments of genomic 
technology are directed not at inherited germ-line pathologies, but at the more 
pervasive problem of cancer. Actually, many instructive parallels can be recognized 
between genetics of the germ-line and tumour (somatic) genetics; not least the 
importance, both in the evolution of species and in tumorigenesis, of genome 
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rearrangements and of the sequential selection of mutations. As far as evolution is 
concerned, the accurate classification of species was an essential precursor to the 
work of Darwin and other evolutionary biologists, who changed how we think about 
biology forever. In pathology, classification of tumours has long been based on tissue 
of origin and morphological distinctions. While immunohistochemistry has had a 
major role in diagnostics, the molecular revolution has changed the entire rationale 
behind classification, and now no pathologist would attempt to classify a problematic 
tumour without some attention to the underlying genomic structure. Chiang and 
Ellison [7] exemplify this in the case of paediatric brain tumours, where not only is 
wholesale reclassification under way, but some distinct entities, such as CNS 
neuroblastoma with FOXR2 activation, have recently been identified solely on the 
basis of the molecular findings.  
 
While paediatric tumours are in general rare, the same cannot be said for prostate 
cancer. De Bono and colleagues [8] summarise the extraordinary recent progress in 
the understanding of the molecular basis of advanced prostate cancer, whereby 
massively parallel sequencing of both tumour and constitutional DNA and RNA, 
together with methylation studies, have led to the development of numerous targeted 
therapies. These therapies, fully informed by the underlying genomic and epigenomic 
defects, are best exemplified by the use of PARP inhibitors in the treatment of men 
whose tumours lack normal BRCA2 protein [9]. Durable responses, sometimes 
measured in years, have been observed in men who previously would have had only 
months to live. Pathologists can play an important role in identifying candidates for 
genetic testing.  
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These advances would not have been possible without a deep understanding of the 
genomics, but many of these concepts will be new to pathologists. For example, 
Graham and Sottoriva [10] discuss neutral evolution and selection, as well as 
graduated and punctuated evolution, which are well-known to those working in 
evolution-related fields, but which have perhaps surprising relevance for the study of 
cancer genomes. One of the most recent examples of the relevance of understanding 
these evolutionary processes is the discovery that some tumours rapidly accumulate a 
very large number of focal rearrangements as a result of a one-time shattering of their 
genomes – “chromothripsis” [11]. Tumours that undergo chromothripsis at an early 
stage of their development may grow rapidly, foiling attempts at early diagnosis, and 
rendering some treatments ineffective [12]. 
 
Many chemotherapeutic agents work because they damage DNA. Dosages and 
scheduling determines that this damage occurs preferentially in tumour cells rather 
than in normal cells. O’Driscoll’s detailed review [13] focus on defects in components 
of the DNA replication machinery. Loss of control of replication results in a wide 
spectrum of largely congenital disorders, such as Seckel and Meier-Gorlin syndrome, 
emphasizing its critical role in normal development. Cancer is also a consequence of 
mutations in the genes encoding these proteins (as discussed in the final cancer review 
of this Annual Review Issue by Glaire et al. [14]). One area of increasing interest is 
disorders of replication stress, and therapies are now being developed to promote this, 
hoping to result in mitotic catastrophe and tumour cell death. 
 
Vastly better outcomes for patients with breast cancer have been achieved by 
improvements in treatment and to a certain extent, by earlier diagnosis. The latter, 
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though, has come at the price of over-diagnosis [15], particularly of early stage 
(“stage 0”) breast cancer, also known as ductal carcinoma in situ (DCIS). Casasent et 
al [16] take on the challenge of using modern genomic technology to answer a critical 
question - which patients with DCIS are most likely to progress to invasive ductal 
carcinoma (IDC)? They apply three models to the available data -  independent 
evolution, evolutionary bottlenecks and multiclonal invasion -  to try to answer this 
critical question. In so doing, they outline the clinical consequences of each model. In 
the independent model, targeting any one biomarker would be unlikely to be helpful, 
whereas in the bottleneck and multiclonal models, identifying the key “truncal” 
mutations, that are common to DCIS and IDC could be of value, with the added 
complexity of the need to consider interactions in the multiclonal model. The authors 
posit that new technologies may help in distinguishing between these models, but 
consider the bottleneck model to be the most consistent with the existing data. 
 
Lam et al [17] bring us up to date with an inherited cancer syndrome – tuberous 
sclerosis -  that exemplifies some of the excitement, as well as the major challenges of 
clinical cancer genetics. For example, it is a remarkably pleiotropic syndrome and 
because a sizeable fraction of cases may have mosaic mutations not detected in blood 
DNA by Sanger sequencing, subtle manifestations may go unnoticed. But because 
TSC1 and TSC2 have inhibitory inputs to the mTOR signalling pathway, and loss of 
TSC1/2 results in its activation, drugs such as sirolimus, that inhibit mTORC1, have 
had remarkable success in treating some of the benign but serious tumours that occur 
in this syndrome. 
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Tomlinson and colleagues [14] round out the cancer section of this Annual Review 
Issue with their update on polymerase proofreading-associated polyposis (PPAP), a 
new polyposis syndrome identified by the groups of Richard Houlston and Ian 
Tomlinson several years ago. They use PPAP as an opportunity to point out the 
necessity to examine both the germline and the somatic variants present in a tumour 
and to include consideration of identified variants in the evolving field of precision 
medicine. While recognizing the potential power of this approach, they rightly point 
out the Achilles’ heel – when individual variants are so rare, and therapies are based 
on “exceptional responders”, how can one combine a desire for precision with the 
kind of evidence base that epidemiologists require and publicly-funded health systems 
will expect? 
 
A key area of difficulty in somatic cell genetics, both in cancer and when considering 
other conditions caused by mosaic mutations [18], is the detection of mutations that 
may be at low level and spatially restricted. This is also an important consideration for 
disorders due to mutations of the mitochondrial genome, in which mutant genomes 
are often present in varying proportions in the cell (heteroplasmy). Alston et al. [19] 
survey this area of human genetic disease, which is of great complexity as a result not 
only of heteroplasmy, but of the interactions between mitochondrially-encoded 
proteins and the much larger number of mitochondrial proteins encoded by the 
nuclear genome. An in-depth review of the biology of one nuclear-encoded 
mitochondrial protein, PINK1, is given by Arena and Valente [20]. They not only 
highlight the limitations of mouse knockout models in recapitulating the autosomal 
recessive Parkinson’s disease caused by PINK1 germline mutations, but also 
emphasize the pleomorphic effects mediated by this one protein in different contexts. 
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We complete our eclectic survey of genetics in pathology with four reviews dealing 
with specific areas of development and organismal homeostasis. Crist [21] focuses on 
the problem of muscle regeneration and repair, which is central to a range of inherited 
muscular dystrophies as well as non-genetic myopathies. In addition to reviewing the 
genetic control of myogenic specification, he considers the challenges inherent in 
recapitulating and controlling the activity of muscle stem cells in vitro, including the 
prospects for targeted gene editing.  
 
Two contributions deal with genetic insights into vascular biology; Ma and Chung 
[22] describe current knowledge of the genetic contributions to pulmonary 
hypertension, while Wetzel-Strong et al. [23] discuss the genetics of vascular 
malformations. A wide range of the latter, some inherited as Mendelian traits and 
others caused exclusively by somatic mutations, are caused predominantly by 
mutations in signalling pathways, rather than structural vascular components, 
providing unexpected information about the crucial role of cell-cell communication in 
the maintenance of normal vascular integrity. 
 
Finally, Mitchison and Valente review the bewildering spectrum of human pathology 
that results from genetic abnormalities of the cilia, both motile and non-motile [24]. 
These “ciliopathies” can show single- or multi-system involvement, and clinical 
presentations as diverse as retinopathy or congenital heart disease. Disorders 
previously categorized as quite distinct from one another have been shown to result 
from mutations in the same gene; the authors thus emphasize the need to move away 
from disease classifications based on isolated phenotypic features, in favour of those 
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based on aetiology. 
 
 
Summary 
 
With some 7,000 rare inherited genetic disorders and a further vast range of genetic 
pathology that could have been sampled from any branch of oncology, we have 
inevitably had space here only to offer a few glimpses, rather than to display a clear 
and full perspective of our subject. Despite this, we hope that readers of The Journal 
of Pathology will find at least one article that helps to catalyse the further exploitation 
of genetics in Understanding Disease– which, of course, is our long-term aim.  
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